Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited.
- License Information
-
More Information
Article History
Received: 27 April 2024
Accepted: 24 July 2024
First Online: 30 July 2024
Declarations
:
: MA has nothing to disclose. CI reports personal fees from Daiichi Sankyo, Edwards Lifesciences, Bristol-Myers Squibb, Otsuka, Cannon Medical Systems, Sumitomo Dainippon, TOA EIYO, MSD, Pfizer, Boehringer Ingelheim, Teijin, Tsumura, and Novartis outside the submitted work. SI reports a grant from the Japan Society for the Promotion of Science outside the submitted work. MK reports grants from the Japanese government during the conduct of the study and the following outside the submitted work: grants from the Japanese government, grants from the Japan Heart Foundation, grants from the Japan Cardiovascular Research Foundation, grants and personal fees from Takeda, personal fees from Daiichi Sankyo, grants and personal fees from Pfizer, grants and personal fees from Ono, grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, grants from Novartis, grants and personal fees from Mitsubishi Tanabe, personal fees from Kowa, personal fees from Otsuka, grants from Sanofi, personal fees from Amgen, personal fees from Toyama-Kagaku, and grants and personal fees from Kureha.
